Search results
Ironwood Pharmaceuticals
WKN: A0X789 / Symbol: IRWD / Name: Ironwood Pharms / Stock / Biotechnology & Medical Research / Mid Cap /
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago. These figures
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
Ironwood Pharmaceuticals IRWD reported an adjusted loss of 1 cent per share for the fourth quarter of 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged
Inovio Pharma
WKN: A115GK / Symbol: INO / Name: Inovio Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Innate Pharma
WKN: A0LCUJ / Name: Innate Pharma / Stock / Biotechnology & Medical Research / Small Cap /
4d Pharma plc
WKN: A1XD45 / Name: 4D Pharma / Stock / Biotechnology & Medical Research / Small Cap /
aTyr Pharma Inc
WKN: A2PM86 / Name: aTyr Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
ESSA Pharma Inc
WKN: A2JKQ4 / Name: ESSA / Stock / Biotechnology & Medical Research / Micro Cap /
Evoke Pharma Inc.
WKN: A3DL9U / Symbol: EVOK / Name: Evoke Pharma / Stock / Pharmaceuticals / Micro Cap /
MEI Pharma Inc.
WKN: A3D69W / Symbol: MEIP / Name: MEI Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Acasti Pharma Inc.
WKN: A3EP78 / Name: Acasti Pharma / Stock / Pharmaceuticals / Micro Cap /